Free Trial
NYSE:BCR

C.R. Bard (BCR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$331.24
$331.24
50-Day Range
N/A
52-Week Range
$222.42
$337.73
Volume
N/A
Average Volume
679,456 shs
Market Capitalization
N/A
P/E Ratio
21.91
Dividend Yield
N/A
Price Target
N/A
BCR stock logo

About C.R. Bard Stock (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

BCR Stock News Headlines

Daniel Bard Won't Return In 2024
Bard image creator is here
Google Bard adds image generation
Bard generates photos now, finally
See More Headlines
Receive BCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C.R. Bard and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2017
Today
5/28/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Health Care Equipment
CUSIP
06738310
CIK
9892
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Timothy M. Ring (Age 59)
    Chairman of the Board, Chief Executive Officer
  • John H. Weiland (Age 61)
    President, Vice Chairman of the Board, Chief Operating Officer
  • James C. Beasley (Age 53)
    Group President
  • Timothy P. Collins (Age 56)
    Group President
  • John P. Groetelaars (Age 50)
    Group President
  • Christopher S. Holland (Age 50)
    Chief Financial Officer, Senior Vice President
  • Samrat S. Khichi (Age 49)
    Senior Vice President, General Counsel, Secretary
  • John A. DeFord Ph.D. (Age 55)
    Senior Vice President - Science, Technology and Clinical Affairs
  • Frank Lupisella Jr. (Age 56)
    Vice President, Controller
  • Betty D. Larson (Age 41)
    Vice President - Human Resources

BCR Stock Analysis - Frequently Asked Questions

How were C.R. Bard's earnings last quarter?

C.R. Bard Inc (NYSE:BCR) issued its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. The business's revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.64 earnings per share.

Is C.R. Bard a good dividend stock?

C.R. Bard (NYSE:BCR) pays an annual dividend of $0.78 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 5.16%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for BCR.

What other stocks do shareholders of C.R. Bard own?

Based on aggregate information from My MarketBeat watchlists, some companies that other C.R. Bard investors own include Abbott Laboratories (ABT), Becton, Dickinson and Company (BDX), Medtronic (MDT), Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), AbbVie (ABBV), Baxter International (BAX), Boston Scientific (BSX), Aflac (AFL) and Stryker (SYK).

This page (NYSE:BCR) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners